News and Announcements
Cre8tek Informational Webinar with Q&A
- Published April 13, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cre8tek Limited (ASX:CR8), owner of high-tech, Artificial Intelligence company, Flamingo Customer experience Inc. Flamingo held an online informational webinar with CEO and founder Dr Catriona Wallace on Tuesday April 18, 2017 at 3pm AEST.
KEY TAKEAWAYS:
The webinar included; a brief presentation on the Flamingo technology platform, sales cycle and customer implementation process. Shareholders also had the opportunity for Q&A following the presentation and also had the opportunity to submit questions prior to the event to an email.
Cre8tek (ASX:CR8) is a listed company that invests in pioneering technology solutions. Cre8tek acquired high profile Australian Fintech business Flamingo Customer Experience Inc. during November 2016. Based in NYC and Sydney, the high-tech Artificial Intelligence (AI) field in the emerging category of Conversational Commerce field.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
